Szpitale Pomorskie Sp. z o.o.

At Szpitale Pomorskie Sp. z o.o. in Gdynia, the strongest area of clinical research is neoplasms, with studies focused on a wide range of cancers. The work includes testing new treatment options and comparing them with current standards to improve outcomes for people with advanced or difficult-to-treat disease.

• Studies in breast cancer, ovarian cancer, and non-small cell lung cancer are especially prominent.
• Research also covers prostate cancer, gastric cancer, and head and neck cancer.
• Several trials aim to evaluate whether newer cancer therapies can improve survival, delay progression, or support treatment after surgery.

This department’s portfolio reflects a broad commitment to advancing cancer care through trials that compare emerging therapies with established treatment approaches.

A major part of the research program is dedicated to breast cancer, including early-stage, locally advanced, and metastatic disease. These trials are designed to improve treatment effectiveness, reduce recurrence risk, and expand options for patients whose cancer has returned or spread.

• Research includes hormone receptor-positive, HER2-negative, and triple-negative breast cancer.
• Some studies focus on treatment after surgery, while others address advanced disease that has already been treated.
• The main goal is to test whether newer therapies can outperform standard cancer treatment.

The site’s breast cancer portfolio shows a strong interest in both earlier intervention and more effective care for advanced disease.

Clinical trials in lung cancer form another major research area, with attention to both non-small cell lung cancer and small cell lung cancer. These studies are exploring new ways to improve survival and control disease in patients with locally advanced, metastatic, or previously treated cancer.

• Trials include patients with KRAS G12C-mutated disease and other advanced lung cancer subtypes.
• Research also examines treatment strategies combined with radiotherapy or immunotherapy.
• The overall purpose is to evaluate whether new therapies can offer better disease control than current standards.

This is an important focus area at the oncology unit, reflecting the need for more effective treatment options in hard-to-manage lung cancers.

The site also conducts substantial research in hemic and lymphatic diseases, especially lymphoma and leukemia. These trials are aimed at improving responses in patients with relapsed, refractory, or high-risk blood cancers.

• Studies cover diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
• Some trials focus on patients who have already received prior treatment and need new options.
• Research objectives include evaluating anti-cancer activity, prolonging progression-free survival, and improving overall disease control.

The hematology-related portfolio highlights a strong interest in therapies for complex and persistent blood cancers.

Another key research field at Szpitale Pomorskie Sp. z o.o. involves female urogenital diseases and selected male urogenital diseases, with a particular emphasis on cancers of the ovary, endometrium, and prostate. These studies are testing new approaches for both newly diagnosed and recurrent disease.

• Trials include ovarian cancer, endometrial cancer, and prostate cancer.
• Several studies focus on advanced or metastatic disease, where treatment choices are often limited.
• The purpose is to assess whether newer therapies can delay progression and improve patient outcomes.

This area shows a balanced mix of research in both gynecologic oncology and prostate cancer care.

Beyond oncology, the site participates in studies within cardiovascular diseases and metabolism. These trials are focused on conditions such as heart failure, myocardial infarction, atrial fibrillation, and chronic kidney disease with hypertension, with the goal of improving long-term health management.

• Research includes myocardial infarction, acute heart failure, and atrial fibrillation.
• Some studies also address chronic kidney disease linked to blood pressure problems.
• The main purpose is to evaluate new therapies that may improve recovery, reduce complications, or support better disease control.

These studies broaden the site’s clinical research profile beyond cancer, showing interest in major chronic diseases affecting adults.